
0:54
Short lecture by Aaron Hartman, MD (YouTube video) discussing safety considerations for the cholesterol absorption inhibitor ezetimibe. The speaker warns clinicians to inform patients that ezetimibe alters biliary sterol composition and may (very rarely) be associated with increased gallstone risk, can cause a minuscule number of mild transient anemia cases, and very rarely causes transaminase elevations (occasional tripling) prompting guideline-directed cessation; recommends periodic transaminase monitoring.










